After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Dr Gaia Coppock comments on how collaborative care among nephrologists is transforming glomerular disease treatment.

Dr Gaia Coppock examines approaches to guide colleagues and patients through the quickly changing landscape of IgA ...

Medtronic plc , a global leader in healthcare technology, today announced it will participate in the 44th annual J.P. Morgan healthcare conference on Monday, January 12, 2026.Geoff Martha, Medtronic ...

Abbott will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, ...

Boston Scientific Corporation tops the list with its strong position in the medical device market. The company’s cardiovascular, rhythm management, and endoscopy product lines have positioned it as a ...

Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Dow Jones set a record close and the S&P 500 hit an intraday high heading into the Christmas holiday. Palantir, Tesla, Google and Nvidia are in buy areas.

Travere Therapeutics (TVTX) just hit a fresh 52 week high after the FDA removed an advisory committee review and relaxed REMS monitoring for FILSPARI, sharpening focus on January’s FSGS approval ...

One analyst believes the company's Filspari has blockbuster potential if it earns FDA approval for a new indication. A decision on that should come very shortly. The stock of commercial-stage biotech ...